Importantly, leukotriene receptor antagonists could be an attractive agent for the immunological control of HCC, which also suppresses ADAM9 enzymatically, resulting in increased treatment efficacy when used in combination with conventional MKIs. The gene discussed is ADAM9; the disease is hepatocellular carcinoma.